NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Forecast, Price & News $2.31 +0.25 (+12.14%) (As of 03:21 PM ET) Add Compare Share Share Today's Range$2.06▼$2.3250-Day Range$0.82▼$2.4952-Week Range$0.62▼$2.69Volume352,780 shsAverage Volume438,411 shsMarket Capitalization$129.18 millionP/E RatioN/ADividend YieldN/APrice Target$6.13 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Aquestive Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside171.0% Upside$6.13 Price TargetShort InterestHealthy3.43% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.12Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.43) to ($0.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector651st out of 1,006 stocksPharmaceutical Preparations Industry326th out of 492 stocks 3.5 Analyst's Opinion Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.13, Aquestive Therapeutics has a forecasted upside of 171.0% from its current price of $2.26.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.43% of the outstanding shares of Aquestive Therapeutics have been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aquestive Therapeutics has recently increased by 4.35%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AQST. Previous Next 4.0 News and Social Media Coverage News SentimentAquestive Therapeutics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Aquestive Therapeutics this week, compared to 1 article on an average week.Search Interest33 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.MarketBeat Follows4 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.75% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.35% of the stock of Aquestive Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.43) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Aquestive Therapeutics (NASDAQ:AQST) StockAquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.Read More Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Stock News HeadlinesMay 31, 2023 | msn.comAquestive Therapeutics releases positive clinical data on anaphylm for anaphylaxis treatmentMay 31, 2023 | finance.yahoo.comAquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical StudyMay 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 31, 2023 | americanbankingnews.comAquestive Therapeutics (NASDAQ:AQST) Shares Up 0.9%May 30, 2023 | entrepreneur.com3 Smart Money Stocks to Invest in TodayMay 16, 2023 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)May 11, 2023 | finance.yahoo.comAre You Looking for a Top Momentum Pick? Why Aquestive Therapeutics (AQST) is a Great ChoiceMay 10, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for Aquestive Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:AQST)May 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 9, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on Aquestive Therapeutics (AQST)May 5, 2023 | msn.comUnusual Call Option Trade in Aquestive Therapeutics (AQST) Worth $6.10KMay 5, 2023 | seekingalpha.comAquestive Therapeutics, Inc. (AQST) Q1 2023 Earnings Call TranscriptMay 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM) and Aquestive Therapeutics (AQST)May 4, 2023 | finance.yahoo.comAquestive Therapeutics First Quarter 2023 Earnings: Beats ExpectationsMay 2, 2023 | finance.yahoo.comAquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 2, 2023 | finance.yahoo.comAquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue EstimatesMay 1, 2023 | markets.businessinsider.comWhat Wall Street expects from Aquestive Therapeutics's earningsApril 25, 2023 | americanbankingnews.comAquestive Therapeutics (AQST) Scheduled to Post Earnings on TuesdayApril 25, 2023 | americanbankingnews.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Expected to Earn Q1 2024 Earnings of ($0.10) Per ShareApril 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Icecure Medical (ICCM)April 20, 2023 | finance.yahoo.comAquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)April 18, 2023 | finance.yahoo.comAquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ETApril 17, 2023 | finance.yahoo.comThere's No Escaping Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Muted Revenues Despite A 63% Share Price RiseApril 1, 2023 | americanbankingnews.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Significant Drop in Short InterestMarch 29, 2023 | finance.yahoo.comAquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global MarketsMarch 10, 2023 | seekingalpha.comAquestive Therapeutics, Inc. (AQST) Q4 2022 Earnings Call TranscriptMarch 10, 2023 | msn.comWedbush Upgrades Aquestive Therapeutics (AQST)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Company Calendar Last Earnings3/08/2023Today5/31/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AQST CUSIPN/A CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees157Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.13 High Stock Price Forecast$8.50 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+197.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,410,000.00 Net Margins-71.16% Pretax Margin-71.16% Return on EquityN/A Return on Assets-58.49% Debt Debt-to-Equity RatioN/A Current Ratio1.08 Quick Ratio0.91 Sales & Book Value Annual Sales$46.54 million Price / Sales2.48 Cash FlowN/A Price / Cash FlowN/A Book Value($2.19) per share Price / Book-0.94Miscellaneous Outstanding Shares55,922,000Free Float50,470,000Market Cap$115.20 million OptionableNot Optionable Beta2.76 Key ExecutivesDaniel BarberPresident, Chief Executive Officer & DirectorCassie JungSenior Vice President-OperationsA. Ernest TothChief Financial Officer & Senior Vice PresidentA. Mark SchobelChief Technology & Innovation OfficerPeter BoydSVP-Human Resources & CommunicationsKey CompetitorsGlycoMimeticsNASDAQ:GLYCAnnovis BioNYSE:ANVSAtossa TherapeuticsNASDAQ:ATOSPardes BiosciencesNASDAQ:PRDSAlaunos TherapeuticsNASDAQ:TCRTView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 116,272 shares on 5/16/2023Ownership: 0.208%HBK Sorce Advisory LLCBought 84,696 shares on 5/16/2023Ownership: 0.151%Jane Street Group LLCBought 23,430 shares on 5/16/2023Ownership: 0.042%Two Sigma Advisers LPSold 9,300 shares on 5/15/2023Ownership: 0.041%Renaissance Technologies LLCBought 56,063 shares on 5/12/2023Ownership: 0.928%View All Insider TransactionsView All Institutional Transactions AQST Stock - Frequently Asked Questions Should I buy or sell Aquestive Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares. View AQST analyst ratings or view top-rated stocks. What is Aquestive Therapeutics' stock price forecast for 2023? 4 analysts have issued 1-year price targets for Aquestive Therapeutics' shares. Their AQST share price forecasts range from $4.00 to $8.50. On average, they predict the company's stock price to reach $6.13 in the next twelve months. This suggests a possible upside of 197.3% from the stock's current price. View analysts price targets for AQST or view top-rated stocks among Wall Street analysts. How have AQST shares performed in 2023? Aquestive Therapeutics' stock was trading at $0.9021 at the start of the year. Since then, AQST shares have increased by 128.4% and is now trading at $2.06. View the best growth stocks for 2023 here. When is Aquestive Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our AQST earnings forecast. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) released its earnings results on Wednesday, March, 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. The company had revenue of $10.68 million for the quarter, compared to analyst estimates of $9.93 million. During the same quarter last year, the firm earned ($0.38) EPS. What guidance has Aquestive Therapeutics issued on next quarter's earnings? Aquestive Therapeutics updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $42.00 million-$46.00 million, compared to the consensus revenue estimate of $39.06 million. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB). When did Aquestive Therapeutics IPO? (AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. What is Aquestive Therapeutics' stock symbol? Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST." Who are Aquestive Therapeutics' major shareholders? Aquestive Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vahanian & Associates Financial Planning Inc. (1.29%), Renaissance Technologies LLC (0.93%), Susquehanna International Group LLP (0.21%), HBK Sorce Advisory LLC (0.15%), Financial Advocates Investment Management (0.04%) and Jane Street Group LLC (0.04%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, John T Maxwell, Keith J Kendall, Lori J Braender and Peter E Boyd. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aquestive Therapeutics' stock price today? One share of AQST stock can currently be purchased for approximately $2.06. How much money does Aquestive Therapeutics make? Aquestive Therapeutics (NASDAQ:AQST) has a market capitalization of $115.20 million and generates $46.54 million in revenue each year. The company earns $-54,410,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis. How many employees does Aquestive Therapeutics have? The company employs 157 workers across the globe. How can I contact Aquestive Therapeutics? Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The official website for the company is www.aquestive.com. The company can be reached via phone at (908) 941-1900 or via email at investorrelations@aquestive.com. This page (NASDAQ:AQST) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.